Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, achieves higher mean weight loss (up to 20.9%) than selective GLP-1 agonists.
Tirzepatide (Zepbound) is a once-weekly injection that targets both GIP and GLP-1 receptors, resulting in an average 20.9% weight loss over 72 weeks, which is higher than semaglutide. It is indicated for adults with obesity or overweight with comorbidities. Like other GLP-1 agonists, it requires lifestyle changes and may cause gastrointestinal side effects. Access may be limited by cost and insurance coverage.
In the SURMOUNT-1 trial, tirzepatide 15 mg weekly achieved mean weight reductions of 20.9% over 72 weeks... This surpasses all previously approved pharmacotherapies, including semaglutide.
Why this rating
Based on phase 3 SURMOUNT-1 trial data.
Source
Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies
Mohammad I. Ullah et al. · Medicines · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →